September 13, 2021Diabetes Technology & TherapeuticsOpen Access

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

View Full Paper

Ask AI

Bookmark

Abstract

These data show the next-generation Eversense CGM system had sustained accuracy and safety up to 180 days, with an improved calibration scheme and survival, using the primary or SBA sensors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garg et al. (2021) studied this question.

synapsesocial.com/papers/69f14cb0c0d8017361865e69 https://doi.org/10.1089/dia.2021.0182

View Full Paper

Ask AI

Bookmark

Abstract

These data show the next-generation Eversense CGM system had sustained accuracy and safety up to 180 days, with an improved calibration scheme and survival, using the primary or SBA sensors.

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

Abstract

Discussion

Cite This Study

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading